Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Aprocitentan in Moderate Hepatic Impairment
NCT04252495Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jun 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of aprocitentan in resistant hypertension (RH) (2 arms), sponsored by Idorsia. Primary endpoints: Maximum Plasma Concentration at Day 14, Area Under the Plasma Concentration-Time Curve from Zero to Last Quantifiable Concentration at Day 14 and 1 more. Started Jun 2020; status: completed.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT04252495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252495.